Results 201 to 210 of about 285,377 (255)

Visualized Clinical-Radiomics Model Based on Non-Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms. [PDF]

Cancer Med
Feng M, Zhao M, Duan X, Hou J, Wang Q, Yin F.   +5 more
europepmc   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

The complete chloroplast genome sequence and phylogenetic analysis of <i>Hydrocleys nymphoides</i> (Alismataceae), an aquatic ornamental plant. [PDF]

Mitochondrial DNA B Resour
Lu X, Ming W.
europepmc   +1 more source

Completion vs. early discontinuation of chemotherapy and the impact on 5‐year all‐cause mortality in women treated for early‐stage breast cancer from 2015 to 2020: A cohort study using a target trial emulation approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Chemotherapy is given for early‐stage breast cancer; however, some patients discontinue before completing all planned cycles. This study investigated the impact of early chemotherapy discontinuation on treatment outcomes. Methods This retrospective cohort study used a target trial emulation framework to conduct a causal analysis of the all‐
Luke Steventon, Chengsheng Ju, Kenneth K. C. Man, Rebecca Roylance, Diego Ottaviani, Chiara Creed, Michal Sladkowski, Alec Wisner, Li Wei, Pinkie Chambers   +9 more
wiley   +1 more source

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

The complete chloroplast genome sequence of <i>Maesa cavinervis</i> (Primulaceae s.l.) and its phylogenetic analysis. [PDF]

Mitochondrial DNA B Resour
Shi QK, Wu NF, Zhang B, Feng Z, Wang GL, Feng Y, Xu B.   +6 more
europepmc   +1 more source

The Poisson CUSUM Chart for Monitoring Small Counts: Addressing the Estimation Uncertainty. [PDF]

Biom J
Heidema S, Stoepker IV, Huits R, Heuvel ERVD.   +3 more
europepmc   +1 more source

Multivariate equivalence and component-wise superiority tests for paired samples. [PDF]

J Biopharm Stat
Hu Y, Chinchilli VM.
europepmc   +1 more source

Elevated sCD25 predicts early infection in patients with major burns. [PDF]

Crit Care
Hurtado-Navarro L, Flores-Cabeza E, Mata-Martínez P, Sánchez-Sánchez M, Terrón-Arcos V, Martín-Flórez C, Cachafeirio L, Vejo-Gutiérrez J, Fernández-Felipe J, Lozano-Rodríguez R, Córdoba L, de Santa María-Diez GS, Del Prado-Montero J, Rigor-Pérez JG, de Diego RP, Del Fresno C, Cueto FJ, López-Collazo E.   +17 more
europepmc   +1 more source